Scholars Central

Conference abstractPublished 2015

SV40 T/t-common polypeptide enhances the sensitivity of HER2-overexpressing human cancer cells to anticancer drugs Cisplatin and Doxorubicin

Authors: Won-Bo Wang, Shu-Ping Hsueh

National Taiwan University, Taiwan

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

HER2-overexpressing cancer cells are resistant to cisplatin (CDDP) and doxorubicin (DXR). Previously, we reported that SV40 T/t-common polypeptide can specifically induce apoptosis in many HER2-overexpressing cancer cells but not in non-HER2- overexpressing cancer cells. Here, we report that SV40 T/t-common polypeptide could specifically sensitize HER2-overexpressing cancer cells to CDDP and DXR and specifically enhance CDDP or DXR-induced apoptosis in these cells. This activity of T/t-common may be attributed to its ability to down-regulate Bcl-2 and Bcl-XL and to modulate ERK and JNK activities in CDDP or DXR-treated HER2-overexpressing cancer cells. T/t-common could enhance the antitumor activity of DXR on HER2-overexpressing ovarian tumor in NOD/SCID mice, suggesting that combination therapy using T/t-common and chemotherapeutic agents may provide a new approach for treating HER2-overexpressing cancers

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Pharmaceutics & Drug Delivery Research.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmaceutics & Drug Delivery Research
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Won-Bo Wang”
  • BylineArticles whose byline prints “Shu-Ping Hsueh”